Contact information
NDM Research Building, Roosevelt Drive, Oxford OX3 7FZ UK
Paul Brennan
PhD, FRSC
Professor of Medicinal Chemistry
- Director – Centre for Medicines Discovery
- Director of Chemistry – Chemical Probes Portal
My research group works at the interface of chemistry and biology to design probes and inhibitors to investigate the intricate workings of human proteins and cells, with particular interest in epigenetic proteins, small GTPases, and dementia. Research interests include medicinal chemistry, fragment- and structure-based drug design, computational chemistry, organic synthesis, and biochemistry. The group is part of the Alzheimer's Research UK Oxford Drug Discovery Institute (ODDI), and Centre for AI in Precision Medicine at the University of Oxford.
More Information
Recent publications
-
Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor.
Journal article
Xiong Y. et al, (2024), Journal of medicinal chemistry
-
Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM.
Journal article
Bashore FM. et al, (2024), PloS one, 19
-
Discovery of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic approach for Alzheimer's disease.
Journal article
Du Y. et al, (2023), The Journal of biological chemistry
-
Structural Premise of Selective Deubiquitinase USP30 Inhibition by Small-Molecule Benzosulfonamides
Journal article
O'Brien DP. et al, (2023), Molecular & Cellular Proteomics, 22, 100609 - 100609
-
The X-linked histone demethylases KDM5C and KDM6A as regulators of T cell-driven autoimmunity in the central nervous system.
Journal article
Fazazi MR. et al, (2023), Brain research bulletin